^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Cholangiocarcinoma

    Related cancers:
    18h
    Senior Adult Hepatobiliary Prehab Study (clinicaltrials.gov)
    P=N/A, N=25, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Nov 2026 | Trial primary completion date: Apr 2026 --> Nov 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    19h
    Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial
    22h
    IL-33/ST2 signaling promotes intrahepatic cholangiocarcinoma through reprogramming macrophage polarization via MAPK pathway. (PubMed, Exp Cell Res)
    IL-33/ST2 signaling drives ICC progression by promoting M2 macrophage polarization via the MAPK pathway. Targeting this axis may represent a novel therapeutic strategy for ICC.
    Journal
    |
    IL33 (Interleukin 33)
    22h
    Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    23h
    Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA): an International Randomized Controlled Multicenter Trial (clinicaltrials.gov)
    P4, N=400, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    New P4 trial
    1d
    The YTHDC1-m6A-MEG3 Regulatory Axis in Radiation-Induced Liver Injury: Deciphering Early-Stage Epitranscriptomic Alterations and Molecular Dynamics. (PubMed, J Inflamm Res)
    We further demonstrated that MEG3 expression is tightly controlled by the METTL3-YTHDC1 axis, and YTHDC1-mediated recognition of m6A-modified MEG3 is essential for the progression of RILI. These insights establish the YTHDC1-MEG3 pathway as a key molecular driver of RILI and provide a framework for the design of targeted therapies to mitigate RILI.
    Journal
    |
    YTHDC1 (YTH Domain Containing 1) • MEG3 (Maternally Expressed 3) • METTL3 (Methyltransferase Like 3)
    2d
    adIVO: Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New P2 trial
    |
    Tibsovo (ivosidenib)
    2d
    Double-negative αβ T lymphocytes: What are the etiological considerations? (PubMed, Rev Med Interne)
    We report a case illustrating how the investigation of a proliferation of double-negative αβ T lymphocytes led to the diagnosis of cholangiocarcinoma. Although a direct link between the two cannot be proven, we hypothesize that tumor antigenic stimulation selected a T lymphocyte clone.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    2d
    Demonstration of SLU7 as a new cancer target. (PubMed, Biomed Pharmacother)
    Our in vivo data demonstrate that SLU7 is a promising, versatile target for possibly diverse cancers. Its multimodal mechanism offers potential to overcome tumor heterogeneity, reverse immune tolerance, and enhance immunotherapy efficacy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NCL (Nucleolin)
    3d
    Case report and literature review: primary hepatic leiomyosarcoma with misdiagnosis and SDHB positive expression. (PubMed, Front Oncol)
    SDHB positivity may indicate favorable tumor biology, but further studies are needed to validate its prognostic value. Surgical resection remains curative for localized PHL.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    3d
    Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma. (PubMed, medRxiv)
    Prior molecular studies have focused mainly on the DNAJB1-PRKACA fusion gene, which is pathognomonic for FLC, but no reliable circulating biomarker has been established for FLC diagnosis or disease monitoring...Routine measurement of serum PCT could facilitate earlier recognition of FLC and also provide a non-invasive tool to track treatment response. Future research should validate these findings prospectively, explore the biological mechanisms underlying CALCA overexpression in FLC, and assess whether PCT-guided monitoring can predict prognosis, improve patient outcomes or clinical trial design in this rare malignancy.
    Journal
    |
    AFP (Alpha-fetoprotein) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha) • CA 19-9 (Cancer antigen 19-9)
    |
    DNAJB1-PRKACA peptide vaccine